Page 101 - 80_03

M.
Ruperto
López,
G.
Barril
Cuadrado

32.
Goicoechea,
M.;
Martin,
J.;
Des,
P.;
Quiroga,
JA.;
Ortiz,
A.;
Carreno,
V.;
et
al.
Role
of
cytokines

in
the
response
to
erythropoietin
in
hemodialysis
patients.
Kidney
Int.54,
1337-­-1343

(1998).

33.
Panichi,
V.;
Rosati,
A.;
Bigazzi,
R.;
Paoletti,
S.;
Mantuano,
E.;
Beati,
S.;
et
al.
Anaemia
and

resistance
to
erythropoiesis-­-stimulating
agents
as
prognostic
factors
in
haemodialysis

patients:
results
from
the
RISCAVID
study.
Nephrol.
Dial.
Transplant.26,
2641-­-2648

(2011).

34.
Barany,
P.;
Vino-­-Filho,
JC.;
Bergstrom,
J.;
High
C-­-reactive
protein
is
a
strong
predictor
of

resistance
to
erythropoietin
in
hemodialysis
patients.
Am.
J.
Kidney
Dis.29,
565-­-568

(1997).

35.
Gracia-­-Iguacel,
C.;
Gonzalez-­-Parra,
E.;
Perez-­-Gomez,
MV.;
Mahillo,
I.;
Egido,
J.;
Ortiz,
A.;
et
al.

Prevalence
of
protein-­-energy
wasting
syndrome
and
its
association
with
mortality
in

haemodialysis
patients
in
a
centre
in
Spain.
Nefrologia.
33,
495-­-505
(2013).

36.
Akgul,
A.;
Bilgic,
A.;
Sezer,
S.;
Ozdemir,
FN.;
Olcay,
I.;
Arat,
Z.;
et
al.
Effect
of
protein-­-energy

malnutrition
on
erythropoietin
requirement
in
maintenance
hemodialysis
patients.

Hemodial.
Int.11,
198-­-203
(2007).

37.
Cuesta,
GC.;
Poveda-­-Andres,
JL.;
Garcia,
PJ.;
Roma,
SE.;Cost
minimisation
analysis
for

darbepoetin
alpha
vs.
epoetin
alpha
in
chronic
kidney
disease
patients
on
haemodialysis.

Farm.
Hosp.
34,
68-­-75
(2010).

38.
Sitter,
T.;
Bergner,
A.;
Schiffl,
H.
Dialysate
related
cytokine
induction
and
response
to

recombinant
human
erythropoietin
in
haemodialysis
patients.
Nephrol.
Dial.

Transplant.15,
1207-­-1211
(2000).

39.
Panichi,
V.;
Rosati,
A.;
Paoletti,
S.;
Ferrandello,
P.;
Migliori,
M.;
Beati,
S.;
et
al.
A
vitamin
E-­-
coated
polysulfone
membrane
reduces
serum
levels
of
inflammatory
markers
and

resistance
to
erythropoietin-­-stimulating
agents
in
hemodialysis
patients:
results
of
a

randomized
cross-­-over
multicenter
trial.
Blood.
Purif.32,
7-­-14
(2011).

554